Abstract：Objective To evaluate the efficacy and safety of multimodal blood management strategy in blood transfusion during perioperative period of primary unilateral total knee arthroplasty (TKA) and total hip arthroplasty (THA).Methods Prospectively recruited 403 patients (285 of whom underwent TKA and 118 of whom underwent THA) were admitted to the Department of Joint Surgery of Xijing Hospital between November 2015 and October 2016 as the study group, while records of 582 patients (393 of whom underwent TKA and 189 of whom underwent THA) between June 2014 and October 2015 were also investigated as the controls. Two groups were basically well-matched on separate index in baseline characteristics (all P values＞0.05). Tranexamic acid was used in all patients, and perioperative multimodal blood management was implemented in the study group. Blood transfusion rate, maximum decline of hemoglobin, intraoperative blood loss, drainage volumes and the incidence of deep vein thrombosis, pulmonary thromboembolism and other postoperative complication were assessed.Results Blood transfusion rate of study group and controls were 1.2% (5/403) and 8.2% (48/582). Specifically, blood transfusion rate in patients undergoing TKA was 0.7% (2/285) and 6.9% (27/393) in the study group and controls, while patients underwent THA was 2.5% (3/118) and 11.8% (21/189) in both group (χ2=22.962, 15.353 and 7.402, all P values＜0.01). Maximizing hemoglobin was (29.62±11.36) g/L for study group and (34.37±12.88) g/L for controls in TKA patients, and as for THA patients, this parameter was (33.29±11.56) g/L and (37.14±9.42) g/L (t'=5.078 and 3.042, all P values<0.01). Moreover, intraoperative blood loss was (91.35±58.79) mL and (157.90±71.35) mL for study and control group in TKA patients, while (172.42±65.64) mL and (246.12±87.89) mL in THA patients, respectively (t'=13.271 and 8.378, all P<0.01). There was an insignificant trend toward incidence of deep vein thrombosis [0.74% (3/403) for study group and 0.85% (5/582) for controls (χ2=0.039, P>0.05)].Conclusions Multimodal blood management may decrease the need for allogeneic blood transfusion and may contribute to improved hemoglobin level of patients following primary unilateral THA and TKA. Moreover, this strategy does not increase the chance for postoperative complications, leading to a positive effect on outcome.
关健, 曹晓瑞, 王刚, 康飞科, 朱锦宇, 韩一生, 朱庆生. 多模式血液管理策略在初次单侧膝、髋关节置换术中的临床应用[J]. 中华解剖与临床杂志, 2017, 22(2): 116-120.
Guan Jian, Cao Xiaorui, Wang Gang, Kang Feike, Zhu Jinyu, Han Yisheng, Zhu Qingsheng.. Multimodal blood management strategy in primary unilateral total knee or hip arthroplasty. Chinese Journal of Anatomy and Clinics, 2017, 22(2): 116-120.
Dieppe P, Lim K, Lohmander S. Who should have knee joint replacement surgery for osteoarthritis？[J]. Int J Rheum Dis, 2011, 14(2): 175-180. DOI:10.1111/j.1756-185X.2011.01611.x
[2]
Sehat KR, Evans RL, Newman JH. Hidden blood loss following hip and knee arthroplasty. Correct management of blood loss should take hidden loss into account[J]. J Bone Joint Surg Br, 2004, 86(4): 561-565. DOI:10.1302/0301-620X.86B4.14508
[3]
Senthil Kumar G, Von Arx OA, Pozo JL. Rate of blood loss over 48 hours following total knee replacement[J]. Knee, 2005, 12(4): 307-309. DOI:10.1016/j.knee.2004.08.008
[4]
Gonzalez-Porras JR, Colado E, Conde MP, et al. An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty[J]. Transfus Med, 2009, 19(1): 35-42. DOI:10.1111/j.1365-3148.2009.00908.x
[5]
Helm AT, Karski MT, Parsons SJ, et al. A strategy for reducing blood-transfusion requirements in elective orthopaedic surgery. Audit of an algorithm for arthroplasty of the lower limb[J]. J Bone Joint Surg Br, 2003, 85(4): 484-489. DOI:10.1302/0301-620x.85b4.13615
Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study[J]. N Engl J Med, 1996, 334 (26): 1685-1690. DOI:10.1056/NEJM199606273342601
[8]
Practice Guidelines for blood component therapy: a report by the American society of anesthesiologists task force on blood component therapy[J]. Anesthesiology, 1996, 84(3): 732-747. DOI:10.1097/00000542-199603000-00032
[9]
Zhao YC, Yan G, Wei C, et al. Reduced blood loss after intra-articular tranexamic acid injection during total knee arthroplasty: a meta-analysis of the literature[J]. Knee Surg Sports Traumatol Arthrosc, 2014, 22(12): 3181-3190. DOI:10.1007/s00167-013-2814-3
Rosencher N, Kerkkamp HE, Macheras G, et al. Orthopedic surgery transfusion hemoglobin european overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe[J]. Transfusion, 2003, 43(4): 459-469. DOI:10.1046/j.1537-2995.2003.00348.x
[12]
Cuenca J, Garcia-Erce JA, Martinez F, et al. Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogeneic blood after knee replacement surgery[J]. Transfusion, 2006, 46(7): 1112-1119. DOI:10.1111/j.1537-2995.2006.00859.x
[13]
Lin S, McKenna SJ, Yao CF, et al. Effects of hypotensive anesthesia on reducing intraoperative blood loss, duration of operation, and quality of surgical field during orthognathic surgery: a systematic review and meta-analysis of randomized controlled trials[J]. J Oral Maxillofac Surg, 2017, 75(1): 73-86. DOI:10.1016/j.joms.2016.07.012
[14]
Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group[J]. N Engl J Med, 1999, 340(6): 409-417. DOI:10.1056/NEJM199902113400601
[15]
Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature[J]. Anesthesiology, 2010, 113(2): 482-495. DOI:10.1097/ALN.0b013e3181e08e97
[16]
Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial[J]. Ann Intern Med, 2000, 133(11): 845-854. DOI:10.7326/0003-4819-133-11-200012050-00008
[17]
Olijhoek G, Megens JG, Musto P, et al. Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial[J]. Transfusion, 2001, 41(7): 957-963. DOI:10.1046/j.1537-2995.2001.41070957.x
[18]
So-Osman C, Nelissen RG, Koopman-van Gemert AW, et al. Patient blood management in elective total hip- and knee-replacement surgery (Part 1): a randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive transfusion policy in erythropoietin-eligible patients[J]. Anesthesiology, 2014, 120(4): 839-851. DOI:10.1097/ALN.0000000000000134
[19]
Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease[J]. Br Med Bull, 1994, 50(2): 272-298. DOI:10.1093/oxfordjournals.bmb.a072892
[20]
MacGillivray RG, Tarabichi SB, Hawari MF, et al. Tranexamic acid to reduce blood loss after bilateral total knee arthroplasty: a prospective, randomized double blind study[J]. J Arthroplasty, 2011, 26(1): 24-28. DOI:10.1016/j.arth.2009.11.013
[21]
Chen X, Cao X, Yang C, et al. Effectiveness and safety of fixed-dose tranexamic acid in simultaneous bilateral total knee arthroplasty: a randomized double-Blind controlled trial[J]. J Arthroplasty, 2016, 31(11): 2471-2475. DOI:10.1016/j.arth.2016.04.003
2017, Vol. 22 
